A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06777316. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations
Study identification
- NCT ID
- NCT06777316
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Cogent Biosciences, Inc.
- Industry
- Enrollment
- 110 participants
Conditions and interventions
Conditions
- Advanced Solid Tumors
- Cholangiocarcinoma
- FGFR2 Gene Amplification
- FGFR2 Gene Fusion/Rearrangement
- FGFR2 Gene Short Variants
- FGFR2 Genetic Alterations
- FGFR3 Gene Amplification
- FGFR3 Gene Fusion/Rearrangement
- FGFR3 Gene Short Variants
- FGFR3 Genetic Alterations
- Intrahepatic Cholangiocarcinoma (Icc)
- Other Solid Tumors, Adult
Interventions
- CGT4859 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 21, 2025
- Primary completion
- Feb 28, 2027
- Completion
- May 31, 2027
- Last update posted
- Apr 16, 2026
2025 – 2027
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford Cancer Institute | Palo Alto | California | 94305 | — |
| Mayo Clinic Jacksonville | Jacksonville | Florida | 32224 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| University of Chicago Medicine Comprehensive Cancer Center | Chicago | Illinois | 60637 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Mayo Clinic Rochester | Rochester | Minnesota | 55905 | — |
| The Christ Hospital | Cincinnati | Ohio | 45219 | — |
| Taussig Cancer Center - Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| Fox Chase cancer Center | Philadelphia | Pennsylvania | 19111 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Huntsman Cancer Institute - University of Utah | Salt Lake City | Utah | 84112 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06777316, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06777316 live on ClinicalTrials.gov.